Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the HSG 2022 Annual Meeting; November 2022. Tampa, FL. [abstract] J Huntingtons Dis. 2022 Oct 31; 11(s1):S31. Previously presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting. doi: 10.3233/JHD-229005
Ling W, Nadipelli VR, Solem CT, Farabee D, Ronquest NA, Perrochet B, Learned SM, Deshpande CG, Heidbreder C. Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment. Subst Abuse Rehabil. 2019 Jun 5;10:13-21. doi: 10.2147/SAR.S198361
Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019 Jan 29;2019(4625787). doi: 10.1155/2019/4625787
Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018 Sep 21;9:59-78. doi: 10.2147/SAR.S150253
Mandeville K, Valentic M, Ivankovic D, Pristas I, Long J, Patrick H. Quality assurance of registries for health technology assessment. Int J Technol Assess Health Care. 2018;34(4):360-7.
Poulos C, Kinter E, van Beek J, Christensen K, Posner J. Preferences of patients with multiple sclerosis for attributes of injectable multiple sclerosis treatments in the United Kingdom and France. Int J Technol Assess Health Care. 2018 Jan;34(4):425-33. doi: 10.1017/S0266462318000491
Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, Han JJ. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abuse Rehabil. 2016 Sep 16;7:131-41. doi: 10.2147/SAR.S108302
Basarir H, Brennan A, Jacques R, Pollard D, Stevens K, Freeman J, Wales J, Price K. Cost-effectiveness of structured education in children with type-1 diabetes mellitus. Int J Technol Assess Health Care. 2016 Jan;32(4):203-11.
Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473
Moloney R, Mohr P, Hawe E, Shah K, Garau M, Towse A. Payer perspectives on future acceptability of comparative effectiveness and relative effectiveness research. Int J Technol Assess Health Care. 2015 Jan;31(1-2):90-8. doi: 10.1017/S0266462315000203
Ara R, Basarir H, Keetharuth AD, Barbieri M, Weatherly HL, Sculpher MJ, Ahmed H, Brown S. Are policy decisions on surgical procedures informed by robust economic evidence? A systematic review. Int J Technol Assess Health Care. 2014 Oct;30(4):381-93. doi: 10.1017/S0266462314000531
Mauskopf J, Chirila C, Masaquel C, Boye KS, Bowman L, Birt J, Grainger D. Relationship between financial impact and coverage of drugs in Australia. Int J Technol Assess Health Care. 2013 Jan 1;29(1):92-100.
Mauskopf J, Walter J, Birt J, Bowman L, Copley-Merriman C, Drummond M. Differences among formulary submission guidelines: implications for health technology assessment. Int J Technol Assess Health Care. 2011 Jul 1;27(3):261-70.
Reed SD, Friedman JY, Gnanasakthy A, Schulman KA. Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. Int J Technol Assess Health Care. 2003 Mar;19(2):396-406.
Bonfill X, Marzo M, Sentís M, Rossell M, Gallardo X, Rivero E. Evaluation of the regular practice of breast cancer screening in a health area. Int J Technol Assess Health Care. 1996 Apr;12(2):388-94.